cmc - nda requirements and common pitfalls of blas (14of15) redi – may 29-30, 2019
Published 4 years ago • 9.9K plays • Length 1:10:48
Download video MP4
Download video MP3
Similar videos
-
38:21
nda and bla application review process (6of15) redi annual conference – may 29-30, 2019
-
36:55
components of new drug application and biologics license application (5of15) redi– may 29-30, 2019
-
36:06
what can cder do for you? (3of15) redi annual conference – may 29-30, 2019
-
10:31
ora aligned for the future (1of15) redi – may 29-30, 2019
-
41:31
pre-approval inspections: what to expect when being inspected (15of15) redi – may 29-30, 2019
-
19:58
cder industry assistance resources (13of15) redi – may 29-30, 2019
-
27:10
overview of post-approval chemistry, manufacture, and controls (cmc) changes to an nda - redi 2020
-
40:19
cder’s review of the prescribing information (11of15) redi– may 29-30, 2019
-
42:43
regulatory highlights for biosimilars and interchangeables (9of15) redi – may 29-30, 2019
-
34:20
a medical officer’s approach to nda/bla review (8of15) redi annual conference – may 29-30, 2019
-
40:08
nonproprietary name suffix and safety for product design and labels (10of15) redi – may 29-30, 2019
-
41:30
meetings: pre-submission and special programs (4of15) redi annual conference – may 29-30, 2019
-
19:31
an overview of pre-license inspections for biotech products (5/15) global quality
-
34:37
lifecycle changes to chemistry, manufacture, and controls in ndas - redi 2020
-
30:07
questions and panel discussion – post-approval cmc and manufacturing - redi 2020
-
5:05
central line associated infection (clabsi)
-
8:08
fda guidance on biosimilars
Clip.africa.com - Privacy-policy